-
Incidental findings in clinical research: the case of the known unknown
Blair Henry
Editorial: Clinical Investigation
-
Incidental findings in clinical research: the case of the known unknown
Blair Henry
Editorial: Clinical Investigation
-
Incidental findings in clinical research: the case of the known unknown
Blair Henry
Editorial: Clinical Investigation
-
Incidental findings in clinical research: the case of the known unknown
Blair Henry
Editorial: Clinical Investigation
-
Incidental findings in clinical research: the case of the known unknown
Blair Henry
Editorial: Clinical Investigation
-
Incidental findings in clinical research: the case of the known unknown
Blair Henry
Editorial: Clinical Investigation
-
Incidental findings in clinical research: the case of the known unknown
Blair Henry
Editorial: Clinical Investigation
-
Incidental findings in clinical research: the case of the known unknown
Blair Henry
Editorial: Clinical Investigation
-
Can we improve the efficiency of early phase trials in pediatric oncology?
Esther Blanco & Darren Hargrave
Clinical Trail Perspective: Clinical Investigation
-
Can we improve the efficiency of early phase trials in pediatric oncology?
Esther Blanco & Darren Hargrave
Clinical Trail Perspective: Clinical Investigation
-
Can we improve the efficiency of early phase trials in pediatric oncology?
Esther Blanco & Darren Hargrave
Clinical Trail Perspective: Clinical Investigation
-
Can we improve the efficiency of early phase trials in pediatric oncology?
Esther Blanco & Darren Hargrave
Clinical Trail Perspective: Clinical Investigation
-
Can we improve the efficiency of early phase trials in pediatric oncology?
Esther Blanco & Darren Hargrave
Clinical Trail Perspective: Clinical Investigation
-
Can we improve the efficiency of early phase trials in pediatric oncology?
Esther Blanco & Darren Hargrave
Clinical Trail Perspective: Clinical Investigation
-
Can we improve the efficiency of early phase trials in pediatric oncology?
Esther Blanco & Darren Hargrave
Clinical Trail Perspective: Clinical Investigation
-
Can we improve the efficiency of early phase trials in pediatric oncology?
Esther Blanco & Darren Hargrave
Clinical Trail Perspective: Clinical Investigation
-
The evolving field of post-transplant therapy in multiple myeloma
Sarah A Holstein, & Philip L McCarthy
Clinical Trail Outcomes: Clinical Investigation
-
The evolving field of post-transplant therapy in multiple myeloma
Sarah A Holstein, & Philip L McCarthy
Clinical Trail Outcomes: Clinical Investigation
-
The evolving field of post-transplant therapy in multiple myeloma
Sarah A Holstein, & Philip L McCarthy
Clinical Trail Outcomes: Clinical Investigation
-
The evolving field of post-transplant therapy in multiple myeloma
Sarah A Holstein, & Philip L McCarthy
Clinical Trail Outcomes: Clinical Investigation
-
The evolving field of post-transplant therapy in multiple myeloma
Sarah A Holstein, & Philip L McCarthy
Clinical Trail Outcomes: Clinical Investigation
-
The evolving field of post-transplant therapy in multiple myeloma
Sarah A Holstein, & Philip L McCarthy
Clinical Trail Outcomes: Clinical Investigation
-
The evolving field of post-transplant therapy in multiple myeloma
Sarah A Holstein, & Philip L McCarthy
Clinical Trail Outcomes: Clinical Investigation
-
The evolving field of post-transplant therapy in multiple myeloma
Sarah A Holstein, & Philip L McCarthy
Clinical Trail Outcomes: Clinical Investigation
-
Newly available treatments for epilepsy: review of clinical studies of lacosamide, ezogabine, perampanel and eslicarbazepine acetate
Steve S Chung
Clinical Trail Outcomes: Clinical Investigation
-
Newly available treatments for epilepsy: review of clinical studies of lacosamide, ezogabine, perampanel and eslicarbazepine acetate
Steve S Chung
Clinical Trail Outcomes: Clinical Investigation
-
Newly available treatments for epilepsy: review of clinical studies of lacosamide, ezogabine, perampanel and eslicarbazepine acetate
Steve S Chung
Clinical Trail Outcomes: Clinical Investigation
-
Newly available treatments for epilepsy: review of clinical studies of lacosamide, ezogabine, perampanel and eslicarbazepine acetate
Steve S Chung
Clinical Trail Outcomes: Clinical Investigation
-
Newly available treatments for epilepsy: review of clinical studies of lacosamide, ezogabine, perampanel and eslicarbazepine acetate
Steve S Chung
Clinical Trail Outcomes: Clinical Investigation
-
Newly available treatments for epilepsy: review of clinical studies of lacosamide, ezogabine, perampanel and eslicarbazepine acetate
Steve S Chung
Clinical Trail Outcomes: Clinical Investigation
-
Newly available treatments for epilepsy: review of clinical studies of lacosamide, ezogabine, perampanel and eslicarbazepine acetate
Steve S Chung
Clinical Trail Outcomes: Clinical Investigation
-
Newly available treatments for epilepsy: review of clinical studies of lacosamide, ezogabine, perampanel and eslicarbazepine acetate
Steve S Chung
Clinical Trail Outcomes: Clinical Investigation
-
Advances in targeted therapy for melanoma: a focus on MEK inhibition
April KS Salama & Kevin B Kim
Review: Clinical Trail Outcomes: Clinical Investigation
-
Advances in targeted therapy for melanoma: a focus on MEK inhibition
April KS Salama & Kevin B Kim
Review: Clinical Trail Outcomes: Clinical Investigation
-
Advances in targeted therapy for melanoma: a focus on MEK inhibition
April KS Salama & Kevin B Kim
Review: Clinical Trail Outcomes: Clinical Investigation
-
Advances in targeted therapy for melanoma: a focus on MEK inhibition
April KS Salama & Kevin B Kim
Review: Clinical Trail Outcomes: Clinical Investigation
-
Advances in targeted therapy for melanoma: a focus on MEK inhibition
April KS Salama & Kevin B Kim
Review: Clinical Trail Outcomes: Clinical Investigation
-
Advances in targeted therapy for melanoma: a focus on MEK inhibition
April KS Salama & Kevin B Kim
Review: Clinical Trail Outcomes: Clinical Investigation
-
Advances in targeted therapy for melanoma: a focus on MEK inhibition
April KS Salama & Kevin B Kim
Review: Clinical Trail Outcomes: Clinical Investigation
-
Advances in targeted therapy for melanoma: a focus on MEK inhibition
April KS Salama & Kevin B Kim
Review: Clinical Trail Outcomes: Clinical Investigation